Published in Drug Week, July 6th, 2001
Fenfluramine is an anti-obesity agent with short-term indications to help with restricted energy intake. Fenfluramine hydrochloride was withdrawn from the U.S. market in September 1997 after reports of heart valve abnormalities in patients who used it. These patients predominately used phentermine hydrochloride in combination with fenfluramine (the much-reported phen-fen combination).
Ravin Davidoff, MB, BCh, from Boston University Medical Center,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.